While the Outperform rating suggests that RBC Capital still sees Aptose Biosciences as a stock likely to outperform the market or its sector, the reduction in the price target could signal to investors that the expected upside, although still present, may not be as high as previously anticipated. This could lead to a neutral short-term impact on the stock price as the market digests the mixed signals of confidence and adjusted expectations.